» Articles » PMID: 26541610

Anticancer Immunotherapy by CTLA-4 Blockade Relies on the Gut Microbiota

Abstract

Antibodies targeting CTLA-4 have been successfully used as cancer immunotherapy. We find that the antitumor effects of CTLA-4 blockade depend on distinct Bacteroides species. In mice and patients, T cell responses specific for B. thetaiotaomicron or B. fragilis were associated with the efficacy of CTLA-4 blockade. Tumors in antibiotic-treated or germ-free mice did not respond to CTLA blockade. This defect was overcome by gavage with B. fragilis, by immunization with B. fragilis polysaccharides, or by adoptive transfer of B. fragilis-specific T cells. Fecal microbial transplantation from humans to mice confirmed that treatment of melanoma patients with antibodies against CTLA-4 favored the outgrowth of B. fragilis with anticancer properties. This study reveals a key role for Bacteroidales in the immunostimulatory effects of CTLA-4 blockade.

Citing Articles

Living Bacteria: A New Vehicle for Vaccine Delivery in Cancer Immunotherapy.

Yang M, Zhong P, Wei P Int J Mol Sci. 2025; 26(5).

PMID: 40076679 PMC: 11900161. DOI: 10.3390/ijms26052056.


Unlocking the Microbial Symphony: The Interplay of Human Microbiota in Cancer Immunotherapy Response.

Chacon J, Faizuddin F, McKee J, Sheikh A, Vasquez Jr V, Gadad S Cancers (Basel). 2025; 17(5).

PMID: 40075661 PMC: 11899421. DOI: 10.3390/cancers17050813.


Gut microbiota as a new target for anticancer therapy: from mechanism to means of regulation.

Sun J, Song S, Liu J, Chen F, Li X, Wu G NPJ Biofilms Microbiomes. 2025; 11(1):43.

PMID: 40069181 PMC: 11897378. DOI: 10.1038/s41522-025-00678-x.


Influence of gut microbial metabolites on tumor immunotherapy: mechanisms and potential natural products.

Li D, Lan X, Xu L, Zhou S, Luo H, Zhang X Front Immunol. 2025; 16:1552010.

PMID: 40066456 PMC: 11891355. DOI: 10.3389/fimmu.2025.1552010.


Fecal microbiota transplantation for the treatment of intestinal and extra-intestinal diseases: Mechanism basis, clinical application, and potential prospect.

Yi D, Li T, Xiao Y, Zhang X, Hao Q, Zhang F Bioeng Transl Med. 2025; 10(2):e10728.

PMID: 40060755 PMC: 11883108. DOI: 10.1002/btm2.10728.


References
1.
Stingele F, Corthesy B, Kusy N, Porcelli S, Kasper D, Tzianabos A . Zwitterionic polysaccharides stimulate T cells with no preferential V beta usage and promote anergy, resulting in protection against experimental abscess formation. J Immunol. 2004; 172(3):1483-90. DOI: 10.4049/jimmunol.172.3.1483. View

2.
Tzianabos A, Pantosti A, Baumann H, Brisson J, Jennings H, Kasper D . The capsular polysaccharide of Bacteroides fragilis comprises two ionically linked polysaccharides. J Biol Chem. 1992; 267(25):18230-5. View

3.
Mazmanian S, Liu C, Tzianabos A, Kasper D . An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell. 2005; 122(1):107-18. DOI: 10.1016/j.cell.2005.05.007. View

4.
Peggs K, Quezada S, Korman A, Allison J . Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol. 2006; 18(2):206-13. DOI: 10.1016/j.coi.2006.01.011. View

5.
Beck K, Blansfield J, Tran K, Feldman A, Hughes M, Royal R . Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006; 24(15):2283-9. PMC: 2140223. DOI: 10.1200/JCO.2005.04.5716. View